[go: up one dir, main page]

WO2009113814A3 - 간암 진단용 단백질성 마커 - Google Patents

간암 진단용 단백질성 마커 Download PDF

Info

Publication number
WO2009113814A3
WO2009113814A3 PCT/KR2009/001225 KR2009001225W WO2009113814A3 WO 2009113814 A3 WO2009113814 A3 WO 2009113814A3 KR 2009001225 W KR2009001225 W KR 2009001225W WO 2009113814 A3 WO2009113814 A3 WO 2009113814A3
Authority
WO
WIPO (PCT)
Prior art keywords
liver cancer
protein marker
early diagnosis
composition
diagnosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/001225
Other languages
English (en)
French (fr)
Other versions
WO2009113814A2 (ko
Inventor
박진영
홍석주
김종민
심영택
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CBSBIOSCIENCE Co Ltd
Original Assignee
CBSBIOSCIENCE Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CBSBIOSCIENCE Co Ltd filed Critical CBSBIOSCIENCE Co Ltd
Priority to US12/922,557 priority Critical patent/US8937165B2/en
Publication of WO2009113814A2 publication Critical patent/WO2009113814A2/ko
Publication of WO2009113814A3 publication Critical patent/WO2009113814A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 간암 조기 진단용 단백질성 마커, 상기 단백질성 마커의 변화를 검출하는 물질을 포함하는 간암 진단용 조성물, 상기 간암 진단용 조성물을 포함하는 간암 진단용 키트, 상기 단백질성 마커를 이용하는 간암 진단 방법, 상기 단백질성 마커를 활용한 간암 치료제 스크리닝 방법, 및 상기 단백질성 마커를 특이적으로 인식하는 항체에 관한 것이다.
PCT/KR2009/001225 2008-03-14 2009-03-12 간암 진단용 단백질성 마커 Ceased WO2009113814A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/922,557 US8937165B2 (en) 2008-03-14 2009-03-12 Proteinic marker for early diagnosis of liver cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080023911A KR101032607B1 (ko) 2008-03-14 2008-03-14 간암 진단용 단백질성 마커
KR10-2008-0023911 2008-03-14

Publications (2)

Publication Number Publication Date
WO2009113814A2 WO2009113814A2 (ko) 2009-09-17
WO2009113814A3 true WO2009113814A3 (ko) 2010-02-18

Family

ID=41065671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001225 Ceased WO2009113814A2 (ko) 2008-03-14 2009-03-12 간암 진단용 단백질성 마커

Country Status (3)

Country Link
US (1) US8937165B2 (ko)
KR (1) KR101032607B1 (ko)
WO (1) WO2009113814A2 (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101153935B1 (ko) 2009-04-06 2012-06-27 대한민국 발암물질에 대한 바이오마커로서 ｅｂｐ50
KR101098940B1 (ko) 2009-04-06 2011-12-28 대한민국 발암물질에 대한 바이오마커로서 ｍｏｅｓｉｎ
CN102713624B (zh) * 2010-01-25 2015-09-09 日东纺绩株式会社 抗Ku86自身抗体的免疫测定方法、其中使用的试剂盒、及使用其的原发性肝细胞癌的判断方法
KR101667088B1 (ko) * 2010-02-12 2016-10-17 니토 보세키 가부시기가이샤 Ｋｕ86 와 이의 자가항체와의 복합체의 면역 측정 방법, 여기에 사용되는 키트 및 이를 이용한 암판정 방법
JP6366608B2 (ja) * 2013-01-22 2018-08-01 ネオプロテオミクス アクチボラグ 癌診断における血小板バイオマーカー
CN103695436B (zh) * 2013-12-05 2015-10-28 河南农业大学 ZmHINT基因在花发育中的应用
CN104280477B (zh) * 2014-11-03 2016-03-30 天津中医药大学 内源性小分子物质在快速检测肝毒性方面的应用
US10151001B2 (en) 2014-12-29 2018-12-11 National Guard Health Affairs Quantification of Lamin C and Lamin A for tumor classification
KR101974509B1 (ko) * 2016-08-04 2019-05-03 재단법인 아산사회복지재단 보체 단백질의 간암 진단 용도
KR102116178B1 (ko) * 2017-05-10 2020-05-27 서울대학교산학협력단 간암 고위험군의 간암 발병 모니터링 또는 진단용 바이오마커 및 그 용도
CN111690740B (zh) * 2019-03-11 2022-09-27 中国医学科学院肿瘤医院 肝细胞癌早筛试剂盒及其制备方法和用途
KR102239722B1 (ko) * 2019-10-21 2021-04-13 동국대학교 경주캠퍼스 산학협력단 암의 방사선 내성을 진단하기 위한 조성물 및 방사선 내성 암 치료용 약학적 조성물
CN111239412A (zh) * 2020-01-20 2020-06-05 复旦大学附属中山医院 聚焦肝细胞肝癌的蛋白小芯片的制备方法
CN111751549A (zh) * 2020-06-08 2020-10-09 郑州大学第一附属医院 蛋白分子在肝癌诊断中的预后方法及其应用
WO2023039417A1 (en) * 2021-09-08 2023-03-16 Ymir Genomics, Llc Biomarkers for detection and treatment of cirrhosis and hepatocellular carcinoma
WO2023068896A1 (ko) * 2021-10-22 2023-04-27 주식회사 넥스아이 Tctp 에피토프 및 이에 특이적으로 결합하는 항체
CN116004833B (zh) * 2023-01-16 2024-11-26 重庆医科大学 一种肝癌组织中pip4k2a剪接变异体的应用
CN118471472B (zh) * 2024-05-22 2025-07-22 中国人民解放军海军军医大学第三附属医院 一种筛选或诊断早期肝癌的标志物、试剂盒、系统及应用
CN119199124A (zh) * 2024-10-21 2024-12-27 浙江大学 基于ldha功能的生物标志物在肿瘤诊断中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030092378A (ko) * 2002-05-29 2003-12-06 박영미 고형암의 진행 정도를 진단하는 방법 및 키트
KR20030092462A (ko) * 2002-05-30 2003-12-06 박영미 암의 진행 정도를 진단하는 방법 및 키트
KR20040039597A (ko) * 2002-11-04 2004-05-12 김진우 인간 ｈｃｃｒ-1 단백질 검출 방법 및 이를 이용한 간암진단키트
US20050089895A1 (en) * 2003-08-13 2005-04-28 Cheung Siu T. Compositions and methods for prognosis and therapy of liver cancer
KR20050076876A (ko) * 2004-01-26 2005-07-29 한국생명공학연구원 간암 유전자 마커 및 이를 이용한 간암 진단킷트
KR100767878B1 (ko) * 2006-11-07 2007-10-17 전북대학교산학협력단 간세포암 진단용 조성물, 이를 포함하는 간세포암 진단키트 및 간세포암 진단방법

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030092378A (ko) * 2002-05-29 2003-12-06 박영미 고형암의 진행 정도를 진단하는 방법 및 키트
KR20030092462A (ko) * 2002-05-30 2003-12-06 박영미 암의 진행 정도를 진단하는 방법 및 키트
KR20040039597A (ko) * 2002-11-04 2004-05-12 김진우 인간 ｈｃｃｒ-1 단백질 검출 방법 및 이를 이용한 간암진단키트
US20050089895A1 (en) * 2003-08-13 2005-04-28 Cheung Siu T. Compositions and methods for prognosis and therapy of liver cancer
KR20050076876A (ko) * 2004-01-26 2005-07-29 한국생명공학연구원 간암 유전자 마커 및 이를 이용한 간암 진단킷트
KR100767878B1 (ko) * 2006-11-07 2007-10-17 전북대학교산학협력단 간세포암 진단용 조성물, 이를 포함하는 간세포암 진단키트 및 간세포암 진단방법

Also Published As

Publication number Publication date
US20110033873A1 (en) 2011-02-10
US8937165B2 (en) 2015-01-20
KR20090098490A (ko) 2009-09-17
WO2009113814A2 (ko) 2009-09-17
KR101032607B1 (ko) 2011-05-06

Similar Documents

Publication Publication Date Title
WO2009113814A3 (ko) 간암 진단용 단백질성 마커
IL225386A (en) A method for identifying cancer by identifying ereg protein
WO2009019368A3 (fr) Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
WO2010090471A3 (ko) 제1형 당뇨병의 신규한 진단 마커
WO2007076439A3 (en) Methods and marker combinations for screening for predisposition to lung cancer
MX345092B (es) Anticuerpos anti-tau humanos,.
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2010120143A3 (ko) 간암 예후 마커
WO2009083009A3 (en) Monoclonal antibodies against cd32b
WO2008022295A3 (en) Prlr-specific antibody and uses thereof
WO2010041892A3 (ko) Aimp1 폴리펩티드의 신규한 용도
WO2007103770A8 (en) Compositions and methods for analyzing renal cancer
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2008111464A1 (ja) スプライシング異常を指標とする抗ガン剤の作用検定方法
WO2007146385A3 (en) Albumin-bound protein/peptide complex as a biomarker for disease
WO2011053565A3 (en) Compositions and methods for detecting a tauopathy
WO2009007846A3 (en) Methods for modifying, isolating, detecting, visualizing, and quantifying citrullinated and/or homocitrullinated peptides, polypeptides and proteins
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
WO2007120766A3 (en) Erythropoietin receptor agonists
WO2008019326A3 (en) Ephb3-specific antibody and uses thereof
IL214210A0 (en) Antibodies that bind psca proteins for diagnosis of cancer
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09719170

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12922557

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09719170

Country of ref document: EP

Kind code of ref document: A2